Compare TBPH & FCBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TBPH | FCBC |
|---|---|---|
| Founded | 2013 | 1874 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 908.9M | 842.5M |
| IPO Year | 2013 | 1996 |
| Metric | TBPH | FCBC |
|---|---|---|
| Price | $16.87 | $47.90 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $18.40 | N/A |
| AVG Volume (30 Days) | ★ 576.4K | 76.5K |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 5.26% |
| EPS Growth | ★ 279.13 | N/A |
| EPS | N/A | ★ 0.63 |
| Revenue | ★ $15,386,000.00 | N/A |
| Revenue This Year | $8.46 | $12.28 |
| Revenue Next Year | N/A | $2.55 |
| P/E Ratio | ★ N/A | $75.75 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.99 | $31.21 |
| 52 Week High | $21.03 | $49.35 |
| Indicator | TBPH | FCBC |
|---|---|---|
| Relative Strength Index (RSI) | 50.80 | N/A |
| Support Level | $16.80 | N/A |
| Resistance Level | $17.17 | N/A |
| Average True Range (ATR) | 0.06 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 33.33 | 0.00 |
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.